BioBoyScout

BioBoyScout

Home
White Papers
Notes
Disclosures
About
Undrilled Acreage
Three banks published on Arrowhead in one week, used different methods, and landed in the same neighborhood. Conventional valuation has no natural place…
 • BioBoyScout
Pelacarsen: The Refutation
Novartis lowered Lp(a) in 8,323 patients and failed to show fewer cardiovascular events. The drug hit its target. The hypothesis did not. That…
 • BioBoyScout
The Number Nobody Is Watching: The Case for Early Approval
Accelerated approval on a tau biomarker has never been granted. Three recent decisions show what it may take, and the answer is not the biomarker…
 • BioBoyScout
The Infusion Chair
Arrowhead presented a second Phase 3 result in Munich on Monday morning. Different disease, different competitor, hardly anybody in the room. The…
 • BioBoyScout

August 2026

Second, With the Better Drug
Arrowhead presented the full SHASTA-3 and SHASTA-4 results in Munich on Sunday. The triglyceride numbers beat the competitor's, and so does the dosing…
 • BioBoyScout
The Adjudicator
Arrowhead announced its ESC schedule this week. Two decisions inside that announcement were not made by Arrowhead, and they are the most informative…
 • BioBoyScout
The Other September Readout
Everyone is watching the brain. The quieter half of Arrowhead's September tests something the brain readout cannot: whether the engine can build a new…
 • BioBoyScout
The Jordan Premium
Why the market cannot price a drug-discovery engine, and what Arrowhead's is really worth. A guide to valuing the machine, not just the medicines it has…
 • BioBoyScout
The Keystone
The rerate case for Arrowhead: one readout this September answers four questions at once, and reprices more than one company. A framework for reading…
 • BioBoyScout
Arrowhead Q3: Don't Read the Quarter, Read the Setup
My quick take on today's numbers and the call. The quarter doesn't matter much, and that is the point. What matters: the biggest prize got closer, and…
 • BioBoyScout
The Execution Engine
Arrowhead develops more clinical candidates, across more tissues, on less money than its larger peers. That engine, not any single drug, is the asset…
 • BioBoyScout

July 2026

© 2026 Robert Toczycki · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture